Stem Cell Therapy of Myocardial Infarction: A Promising Opportunity in Bioengineering

DOI Web Site Web Site Web Site 被引用文献1件
  • Bin Jiang
    Fischell Department of Bioengineering University of Maryland College Park MD 20742 USA
  • Li Yan
    Fischell Department of Bioengineering University of Maryland College Park MD 20742 USA
  • James G. Shamul
    Fischell Department of Bioengineering University of Maryland College Park MD 20742 USA
  • Maxwell Hakun
    Fischell Department of Bioengineering University of Maryland College Park MD 20742 USA
  • Xiaoming He
    Fischell Department of Bioengineering University of Maryland College Park MD 20742 USA

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Myocardial infarction (MI) is a life‐threatening disease resulting from the irreversible death of cardiomyocytes (CMs). Stem cell‐based therapies have been studied for MI treatment over the last two decades with promising outcomes. Here, the past work in this field is critically reviewed to elucidate the advantages and disadvantages of treating MI using pluripotent stem cells (PSCs) including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), adult stem cells, and cardiac progenitor cells. Overall, PSCs (particularly iPSCs) have more advantages than the other cells for cardiac regeneration. However, the use of iPSCs is also facing critical challenges, which may be resolved by using biomaterials to engineer stem cells for reduced immunogenicity, improved immobilization/survival in the heart, and increased integration with the host cardiac tissue to eliminate arrhythmia. Biomaterials have also been applied in the derivation of CMs in vitro to increase the efficiency and maturation of cardiac differentiation. Collectively, a lot has been learned from the past failures of simply injecting intact stem cells or their derivatives in vivo for treating MI, and bioengineering stem cells with biomaterials may be a valuable strategy for advancing stem cell therapy towards its widespread application for MI treatment in the clinic.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ